Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Operating Expenses (2023 - 2025)

Monte Rosa Therapeutics' Other Operating Expenses history spans 2 years, with the latest figure at $59000.0 for Q1 2025.

  • For Q1 2025, Other Operating Expenses changed N/A year-over-year to $59000.0; the TTM value through Dec 2025 reached $59000.0, changed N/A, while the annual FY2025 figure was $59000.0, N/A changed from the prior year.
  • Other Operating Expenses reached $59000.0 in Q1 2025 per GLUE's latest filing, up from $24000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $59000.0 in Q1 2025 to a low of $24000.0 in Q2 2023.